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ORIGINAL ARTICLE
Increased expression of YAP1 in prostate cancer correlates
with extraprostatic extension
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1Molecular  Biology and Genetics  Department,  Faculty  of  Engineering and Natural  Sciences,  Istanbul  Medeniyet  University,
Istanbul 34700, Turkey; 2Pathology Department, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, 34700, Turkey;
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ABSTRACT Objective: Yes associated protein 1 (YAP1) is a member of the Hippo pathway, acting as a transcriptional coactivator. To elucidate
the role of YAP1 and phosphorylated (p)YAP1 in prostate cancer (PCa) tumorigenesis, we investigated their expression in clinical
samples of PCa and cell lines.
Methods: Fifty-four tumor, adjacent nontumor, and prostate intraepithelial neoplasia (PIN) tissues from patients with PCa after
radical prostatectomy were selected from a retrospective cohort and studied using immunohistochemistry (IHC). Protein and
mRNA expression levels of YAP1 were evaluated by Western blot analysis and quantitative real-time reverse transcription PCR,
respectively, in cancer cell lines. Publicly available gene expression datasets were downloaded to analyze YAP1 mRNA and protein
levels in PCa tissue samples.
Results: IHC analysis of PCa tissues revealed that YAP1 staining intensities were moderate to weak in the nucleus and cytoplasm of
tumor cells, whereas adjacent normal epithelia showed strong staining. We observed that benign prostates were characterized by
higher expression levels of both nuclear (P=0.004) and cytosolic (P=0.005) YAP1. pYAP1 staining was weak in the cytoplasm and
absent in the nucleus of all the tissues investigated. YAP1 expression was an indicator of extraprostatic extension (EPE). The level
of YAP1 was negatively correlated with the level of the androgen receptor (AR) in The Cancer Genome Atlas dataset and Western
blot analysis of cell lines.
Conclusions: Our study suggested that YAP1 expression is heterogeneous in PCa tissue samples; therefore, YAP1 might play
different roles in different aspects of PCa progression. This might involve AR–YAP1 interplay in PCa.
KEYWORDS YAP1; pYAP1; PCa
 
Introduction
Prostate cancer (PCa) is the most diagnosed cancer type and
the  second  leading  cause  of  cancer  death  in  men.  Yes
associated  protein  (YAP)  is  a  transcription  co-activator  that
is  negatively  regulated  by  the  Hippo  tumor  suppressor
pathway.  This  pathway  has  a  role  in  cell  proliferation  and
apoptosis.  The  Hippo  pathway  is  stimulated  by  cell-to-cell
contact  and  induces  cell  proliferation  in  normal  cells  until
the  cell  population  reaches  a  certain  density.  When  the  cell
density  is  sufficiently  high,  the  pathway  activates  an
inhibitory switch to stop proliferation and activate apoptosis.
This  proliferation-apoptosis  switch  is  regulated  by  cell
adhesion,  cell  polarity,  cytoskeletal  dynamics,  and
mechanical  forces.  The  Hippo  pathway  regulates  organ  size
in  the  same  manner1.  The  core  component  of  the  Hippo
pathway  in  mammals  is  a  protein  kinase  cascade.  This
cascade  starts  with  mammalian  sterile  twenty-like  1/2
(MST1/2) kinases. These kinases are activated by several intra
and extracellular stimuli. The second kinase in the cascade is
large  tumor  suppressor  1/2  (LATS1/2),  which  is
phosphorylated  by  MST1/2.  MOB  kinase  activator  1A
(MOB1) acts as a cofactor for LATS1. The effector proteins in
this  cascade  are  YAP  and  transcriptional  coactivator  with  a
PDZ-binding  domain  (TAZ).  In  their  unphosphorylated
form,  these  proteins  translocate  into  the  nucleus  and  act  as
transcriptional  cofactors.  Upon  phosphorylation  by
LATS1/2, YAP and TAZ accumulate in the cytoplasm and are
directed to degradation2. The cytoplasmic localization of YAP
is  facilitated  by  binding  of  the  14-3-3  proteins  to  the
phosphorylated  form  of  YAP.  YAP  only  localizes  to  the
nucleus  when  the  pathway  is  inactive,  and  controls  the
expression of differentiation, tissue growth, pro-proliferative,
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and anti-apoptotic genes,  together with several  transcription
factors.  Runt-related  transcription  factor  2  (Runx2),  TEA
domain (TEAD), tumor protein p73 (p73), human epidermal
growth  receptor  4  (ErbB4),  SMAD  family  member  7
(Smad7),  and  SMAD  family  member  1  (Smad1)  are  among
the  transcription  factors  that  YAP  can  bind3,4.  There  are
several  upstream  modulators  of  the  pathway.  Merlin,  a
cytoskeletal protein encoded by Neurofibromatosis 2 (NF2), is
a  positive  regulator  of  the  pathway,  and  therefore  is  an
inactivator  of  YAP.  Ras-association  domain  family  (RASSF)
proteins also activate MST1/25. Other than these well-known
regulators,  E-cadherin,  G  protein-coupled  receptors
(GPCRs), and the leukemia inhibitory factor receptor (LIFR)
have  been  reported  to  play  roles  in  modulation  of  YAP
activity, dependent or independent of the Hippo pathway6.
The  role  of  YAP1  in  oncogenesis  is  still  controversial.
Although YAP1 was initially proven to be proto-oncogenic
and its  expression is  increased in  breast  cancer7,  hepato-
cellular  carcinoma8,  colorectal  cancer9,  gastric  cancer10,
pancreatic  cancer11 ,  and  esophageal  squamous  cell
carcinoma12, other studies showed that YAP1 expression is
decreased, such as in breast13 and prostate14 cancers, claiming
that the protein functions as a tumor suppressor.
There are few studies in the literature analyzing YAP1 level
in PCa tissue samples. Sheng et al.15  evaluated 32 PCa, 15
benign prostatic hyperplasia (BPH), and 15 para-PCa (para-
PCa) tissues. They showed that YAP1 was abundant in cancer
tissue, absent in BPH, and scarce in para-PCa tissues. Their
results indicated that the YAP1 level is positively correlated
with  the  Gleason  score,  tumor,  node,  metastasis  (TNM)
staging, and prostate-specific antigen (PSA) levels. Zhang et
al.16 compared 7 primary therapy-naive PCa tissues with 13
castrate-resistant PCa tissues in terms of YAP1 levels. Little or
no YAP1 was observed in primary samples; however, YAP1
was activated and overexpressed in castrate-resistant cases.
To determine the relevance of the Hippo/YAP pathway in
PCa pathogenesis, we sought to evaluate the expression and
subcellular localization of YAP1 and phosphorylated YAP1
(pYAP1) in prostate  tumors.  We also studied the clinical
significance  of  YAP1  expression  and  its  correlation  with
clinicopathological  parameters  of  PCa.  Furthermore,  to
investigate the relationship between YAP1 and the androgen
receptor  (AR),  we  analyzed  their  expression  levels  using
publicly available data sets as well as by Western blot analysis
in a panel of benign and malignant prostate cell lines.
Materials and methods
Patients and tissue samples
Upon  approval  of  the  protocol  by  the  research  and  ethics
committees,  the  pathology  files  from  the  Pathology
Department  of  the  Istanbul  Medeniyet  University  Hospital
were reviewed. Paraffin blocks were obtained from tissues of
prostatectomy cases (2013 to 2015). The sample set included
54  PCa,  prostate  intraepithelial  neoplasia  (PIN),  and  cancer
adjacent  benign  tissues  that  were  routinely  fixed  in  10%
neutral buffered formalin and embedded in paraffin.
Immunohistochemistry
The  tissues  were  evaluated  both  histochemically  using
hematoxylin-eosin  staining  and  immunohistochemically
using YAP1 and pYAP1 antibodies. Sections of 4 μm were cut
from paraffin blocks that were previously coated with poly-L-
lysine.  Specimen slides  were then deparaffinized with xylene
for  10  min  and  rehydrated.  Hydrogen  peroxide,  phosphate
buffered  saline  (PBS),  and  a  nonspecific  blocking  reagent
(Leica  Biosystems,  Newcastle  upon  Tyne,  UK)  were  applied
as  antigen  retrieval  solutions.  The  tissue  sections  were
incubated  at  room  temperature  for  approximately  90  min
with  primary  antibodies  (anti-YAP1,  diluted  1:400;  anti-
pYAP1,  diluted  1:50;  catalog  No.  12395  and  4911,
respectively;  Cell  Signaling Technology,  Danvers,  MA, USA)
to detect YAP1 and pYAP1 (phosphorylated at Ser127). This
step  was  followed  by  detection  using  the  Bond  Polymer
Refine  kit  for  25  min  on  a  Bond-Max  Autostainer  (Leica
Biosystems),  visualization  with  diaminobenzidine
chromogen,  and  counterstaining  with  hematoxylin.
Cytoplasmic  and  nuclear  staining  of  YAP1  indicated  a
positive sample. The findings were evaluated via quantitative
morphometric analysis.
Evaluation of immunostained samples
All  cases  were  reviewed  by  two  pathologists  (S.O.  and  P.Z.)
who  were  blinded  to  the  origin  of  the  samples.  For  each
patient,  formalin-fixed  paraffin-embedded  tissue  blocks
containing  prostatic  adenocarcinoma,  PIN,  and  cancer
adjacent normal tissue in one block were prepared. YAP1 and
pYAP1  expression  was  evaluated  in  the  nucleus  and
cytoplasm  of  the  tumor,  PIN,  and  tumor  adjacent  normal
epithelia. The intensity was scored as: 0 (negative), 1 (weak),
2 (intermediate), and 3 (strong). Discrepancies in scores were
discussed to obtain a consensus.
Gene expression and protein profiles from
public databases
Several  publicly  available  PCa  datasets  were  used  for  the
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analysis.  All  the  data  were  downloaded  from  cBioPortal
(www.cbioportal.org)17,18.  The  prostate  adenocarcinoma
[The  Cancer  Genome  Atlas  (TCGA);  provisional]  data  set
was  analyzed  to  correlate  YAP1  and  AR  at  the  mRNA  and
protein  levels.  The  prostate  adenocarcinoma  (Fred
Hutchinson  CRC,  Nat  Med  2016)  data  set  was  used  to
analyze  YAP1  mRNA  in  matched  localized  and  metastatic
samples.  Data  about  copy  number  alterations  of  YAP1  were
retrieved  from  prostate  adenocarcinoma,  metastatic
(Michigan,  Nature  2012),  prostate  adenocarcinoma
(MSKCC,  Cancer  Cell  2010),  and  prostate  adenocarcinoma
(Fred  Hutchinson  CRC,  Nat  Med  2016)  data  sets.  The
statistical  analysis  of  the downloaded data was performed in
SPSS 22 (IBM, Armonk, NY, US).
Western blot analysis
Total  cell  lysates  were  prepared  on  ice-cold  lysis  buffer  (20
mM HEPES (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 1
mM EDTA, 5 mM NaF, protease inhibitors, and phosphatase
inhibitors).  Protein  concentrations  were  determined  by  the
Lowry  method  (Bio-Rad,  Hercules,  CA,  USA).  Forty
micrograms  of  protein  in  the  cell  lysates  were  resolved  by
SDS-PAGE,  transferred  to  nitrocellulose  membranes,  and
blocked  with  PBST  (PBS  with  0.1%  Tween  20)  containing
5% (w/v) skimmed milk powder. Signals were detected using
a  WesternBright  Sirius  chemiluminescent  horseradish
peroxidase  (HRP)  substrate  (Advansta  Corporation,  Menlo
Park,  CA,  USA).  Antibodies  and  working  dilutions  for
Western  blot  were:  anti-AR  (1:1000,  EMD  Millipore,
Darmstadt,  Germany),  anti-YAP1,  (1:1000,  Cell  Signaling
Technology),  and  anti-β-Actin  (1:1000,  Cell  Signaling
Technology).  Immunoreactive  protein  bands  were  scanned
using  a  digital  chemiluminescent  imaging  system  (Azure
c300,  Azure  Biosystems,  Dublin,  CA,  USA).  The
housekeeping protein β-Actin served as a loading control.
Quantitative real-time reverse transcription
polymerase chain reaction (qRT-PCR)
Total  RNA  was  extracted  from  each  group  of  PCa  cell  lines
using a Quick RNA MiniPrep Kit (Zymoresearch, Irvine, CA,
USA).  The  total  RNA  was  quantified  using  a  UV
spectrophotometer  (DS-11,  DeNowix,  Wilmington,  DE,
USA),  and  1  μg  RNA was  used  for  the  reverse  transcription
reaction  to  obtain  cDNA.  cDNA  synthesis  was  performed
using  a  SensiFAST  cDNA  Synthesis  Kit  (Bioline,  London,
UK) according to the manufacturer's instructions. The qPCR
reactions were performed with 1 μL of cDNA to amplify the
YAP1  and  AR  mRNA,  with  glyceraldehyde-3-phosphate
dehydrogenase  (GAPDH)  as  the  reference  gene,  using  the
RotorGene Q cycler (Qiagen, Hilden, Germany). The cycling
conditions were as follows: 95 °C for 10 sec, 95 °C for 15 sec,
and 60 °C for 1 min (40 cycles). The forward (F) and reverse
(R) primer sequences for the YAP1, AR, and GAPDH mRNA
obtained  from  Thermofisher  were  as  follows:  YAP1F:  5′-
TGCGTAGCCAGTTACCAACACTG-3′,  YAP1R:  5′-TCGAGA
GTGATAGGTGCCACTG-3′, ARF: 5′-ATCCTCATATGGCCC
AGTGTCAAG-3′,  ARR:  5′-GCTCTCTAAACTTCCCGTGG
CATA-3′,  GAPDHF:  5′-GGAGCGAGATCCCTCCAAAT-3′-
and GAPDHR: 5′-GGCTGTTGTCATACTTCTCATGG-3′.
Statistical analysis
For  the  statistical  analysis  of  staining  intensity  between  and
within  YAP1  and  pYAP1  in  the  cytoplasm  and  nucleus  of
tumors,  benign  tissues,  and  PIN  areas,  the  Kruskal–Wallis
H-test  and  posthoc  pairwise  comparison  tests  were
performed.  The  Kruskal–Wallis  H-test  is  a  nonparametric
method  used  to  test  the  differences  between  two  or  more
groups  of  an  independent  variable  on an  ordinal  dependent
variable.  In our analysis,  the ordinal  dependent variable  was
the staining intensity, and depending on the comparison that
was pursued, the independent variables would be the protein
type  (YAP1  or  pYAP1),  cell  compartment  (nucleus  or
cytoplasm), and tissue type (tumor, benign, PIN). When the
Kruskal–Wallis  H  test  indicated  a  statistical  difference
between  the  groups  of  independent  variables,  we  concluded
that  at  least  one  of  the  groups  of  the  independent  variables
was different from the others. In addition, if this test showed
that  there  was  a  difference  between  the  groups  of  the
independent  variables,  to  identify  which  group  or  groups
were significantly different, we performed a posthoc pairwise
comparison  test  to  explore  these  differences.  When
comparing  the  YAP1  staining  intensity  with  the  clinico-
pathological  parameters,  staining  intensity  was  grouped  as
“positive”  or  “negative”.  The  staining  intensities  3  (strong)
and  2  (intermediate)  were  considered  positive  staining,
whereas  1  (weak) and 0 (negative)  were considered negative
staining. Statistical significance was assumed when P < 0.05.
Results
Expression and subcellular localization of
YAP1 and pYAP1 in human PCa tissues
We  investigated  YAP1  and  pYAP1  expression  using
immunohistochemistry  in  PCa,  PIN,  and  cancer  adjacent
benign  tissue  of  54  radical  prostatectomy  specimens.  YAP1
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was  highly  expressed  both  in  the  cytoplasm  and  nucleus  of
the  benign  tissue,  whereas  it  was  moderately  expressed  in
PIN  and  cancer  tissues  in  both  cellular  locations  (Figure
1A–C).  YAP1  expression  was  decreased  in  PIN  and  cancer
tissues;  benign  tissue  adjacent  to  cancer  tissue  exhibited
stronger  cytoplasmic  and  nuclear  expression  (Table  1,  P  <
0.05). pYAP1 expression levels were low in the cytoplasm and
negative  in  the  nucleus  of  most  cases  (Figure  1D  and  E).
There  was  no  statistically  significant  difference  in  the
expression  of  pYAP1  in  the  cytoplasm  of  all  tissue  types
(Table  1,  P  >  0.05).  The  staining  intensities  of  pYAP1  were
different from each other in the cytoplasm and nucleus of all
tissue types (benign, PIN, and cancer) investigated (Table 1,
P < 0.05).
Correlation of YAP1 and pYAP1 expression
with the clinicopathological features of PCa
The  relationships  between  YAP1  expression  and  the
clinicopathological  characteristics  of  PCa  were  analyzed  by
ordinal regression. We did not find a significant relationship
between the expression of nuclear and cytoplasmic YAP1 and
patients’ (positive) surgical margin, seminal vesicle invasion,
Gleason  score,  and  perineural  invasion.  However,  we
observed  that  high  nuclear  and  cytosolic  YAP1  levels  were
associated  with  extraprostatic  extension (EPE)  (P  <  0.04)  in
PCa  (Table  2).  The  odds  ratio  for  EPE  was  3.61,  indicating
that in the presence of EPE, YAP1 was highly expressed.
A B
C D E
 
Figure 1   Representative photographs of cytoplasmic and nuclear YAP1 immunostaining. (IHC staining, 20×). (A) Benign. (B) PIN. (C) Cancer
tissue areas of PCa patient. (D) pYAP1 immunostaining of the same patient’s PIN. (E) pYAP1 immunostaining of the same patient’s cancer
tissue area. The areas are indicated with arrows.
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Investigation of YAP1 aberrations in PCa
tissue samples using public databases
The  correlation  of  high  YAP1  staining  with  EPE  led  us  to
consider  that  YAP1  may  have  a  role  in  metastasis.  We
selected  the  prostate  adenocarcinoma  (Fred  Hutchinson
CRC, Nat Med 2016) data set because it harbors primary PCa
and  matching  metastatic  tissue.  We  analyzed  YAP1  mRNA
expression  in  13  matched  local  and  metastatic  PCa  tissue
samples.  There  was  no  difference  in  terms  of  YAP1  mRNA
expression between the local and matched metastatic samples
(Figure  2A).  Next,  we  obtained  the  copy  number  alteration
(CNA)  data  for  YAP1  in  three  different  PCa  datasets.  The
results  indicated  that  CNA  for  YAP1  was  much  more
common  in  metastatic  samples  than  in  primary  tumors
(Figure  2B,  C).  These  aberrations  were  very  heterogeneous,
displaying both gains and losses at the YAP1 locus.
Investigation of AR-YAP1 correlation in PCa
tissue samples using public databases and PCa
cell lines
AR is a crucial transcription factor in PCa progression and an
overall  therapy  target.  We  investigated  the  AR-YAP1
correlation  using  TCGA  data.  Interestingly,  AR  and  YAP1
mRNA  levels  were  positively  correlated  (Figure  3A),  while
AR and YAP1 were negatively  correlated at  the protein level
(Figure  3B).  We  obtained  similar  results  in  several  PCa  cell
lines  (Figure  4A,  B,  and  C).  We  assessed  the  level  of  YAP1
and AR proteins using western blotting. The level of YAP1 in
AR-negative  PCa  cell  lines  (DU145  and  PC3)  and  in  an
immortalized  primary  epithelial  cell  line  (RWPE1)  was
higher compared to that in the AR-positive cell lines (LNCaP,
LNCaP-abl, VCaP, DuCaP) (Figure 4A). However, YAP1 and
AR mRNA levels were positively correlated (LNCaP, LNCaP-
abl,  DU145,  PC3,  and  RWPE1)  and  these  results  were  in
agreement  with  the  results  obtained  from  the  datasets
(Figure  4B  and  C).  The  exceptions  to  this  were  the  DuCaP
and VCaP cell  lines,  in which AR and YAP1 were negatively
correlated at both the mRNA and protein levels.
Discussion
In  this  study,  we  investigated  the  expression  patterns  and
localizations  of  YAP1  and  pYAP1  in  PCa,  and  compared
them  with  PIN  and  tumor  adjacent  benign  tissue  using
immunohistochemistry.  After  immunohistochemical
staining,  we  scored  nuclear  and  cytoplasmic  YAP1  and
pYAP1 staining from 0 to 3, considering no staining as 0, low
staining as 1, moderate staining as 2, and strong staining as 3.
We  correlated  the  staining  intensity  with  the
clinicopathological  parameters  of  patients,  which  suggested
that  YAP1  is  an  indicator  of  EPE.  Overexpression  of  YAP1
has  been  observed  in  cervical  tumors19,  breast  cancer7,  and
PCa15. However, decreased or absent expression of YAP1 has
also  been  reported  in  breast13  and  PCa14.  In  an  early  study
investigating  the  YAP1-cancer  association  conducted  by
Zhao  et  al.20,  elevated  and  nuclear-localized  YAP1  was
observed  in  PCa.  The  number  of  patients  and  their  PCa
status  were  not  mentioned  in  the  study,  which  made  it
difficult  to  compare  their  data  with  ours.  Similar  to  a
Table 1   YAP1 and pYAP1 immunostaining in different tissue areas and cellular compartments
YAP1 pYAP1
Cytoplasm Nucleus   Cytoplasm Nucleus
Intensity score 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
Benign (n) 4 8 4 38 12 0 4 38 22 26 5 1 48 0 5 1
PIN (n) 5 9 21 19 14 0 21 19 18 26 10 0 44 0 10 0
Cancer (n) 2 9 27 16 11 0 27 16 14 31 9 0 45 0 9 0
P (different tissue areas) 0.005 0.004 0.077 0.05749
Table  2     Correlat ion  of  YAP1  immunostaining  with
clinicopathological parameters
Positive (n) Negative (n) P Odd ratio
PN inv 37 17
SM 18 36
SV 11 43
EPE 15 39 0.037 3.61
≤ 7 > 7
Gleason
score
32 22
PN inv: Perineural invasion. SM: Surgical margin. SV: Seminal
vesicles  invasion.  EPE:  Extraprostatic  extension.  Negative:
Intensity score 0 and 1. Positive: Intensity score 2 and 3.
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previous evaluation of YAP1 expression in PCa by Hu et al.14,
we also observed that YAP1 expression was decreased in PCa
tissues;  normal  prostate  tissues  adjacent  to  cancer  exhibited
stronger nuclear and cytoplasmic expression of YAP1.
YAP1 is located on chromosome 11q22 and was originally
reported to be a candidate oncogene in mouse mammary
tumors21. Amplification of the 11q22 chromosomal locus was
observed  in  g l ioblastomas 2 2 ,  ora l  squamous-cel l
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Figure 2   CNA and mRNA expression of YAP1 in primary and metastatic PCa samples. (A) There is no statistically significant difference
between mRNA values of YAP1 in 13 primary PCa sample and their matched metastatic lesions. (B) Metastatic PCa samples show high CNA
of YAP1 compared to primary PCa samples. (C) Absolute numbers of cases from B.
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Figure 3   Correlation of YAP1 and AR. (A) Correlation of YAP1 and AR in mRNA level is positive. The correlation coefficients are R=0.437
and R=0.326 according to Spearman rho and Pearson correlation, respectively (P < 0.0001). (B) Correlation of YAP1 and AR in protein level
is negative. The correlation coefficients are R=–0.236 and R=–0.310 according to Spearman rho and Pearson correlation, respectively (P <
0.0001).
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carcinomas23,  and  in  cancers  of  the  pancreas24,  lung25,
ovary26, and cervix27. However, Overholtzer et al.21 could not
detect YAP amplification in more than 100 sporadic human
breast  cancers  using  qPCR  analysis  of  microscopically
dissected  specimens.  Loss  of  heterozygosity  (LOH)  was
reported in early genetic studies of breast cancer and PCa28.
The decrease of YAP1 expression could be explained by LOH
in our study groups; however, further investigations should
be done to test this hypothesis. In contrast to our results, no
differences were found between localized tumors and control
tissues taken from BPH patients in the study by Jiang et al.29.
However,  using  other  patients’  tissues  as  controls  may
represent a complication when interpreting the outcome. In
contrast to our observations, immunohistochemical analysis
of 31 prostate tumors and matching normal tissues revealed
that YAP1 was overexpressed in PCa30.  The assessment of
YAP1 expression in normal prostate (n=9) and PCa tissues
(n=22) using IHC by Kuser-Abali et al.31 showed that YAP1
was amply stained in both cases. Staining of the tissues was
mainly  nuclear,  was  not  uniform,  and  its  intensity  was
heterogeneous, differing from no-staining, low-staining, and
overstaining  within  the  same  samples  and  among  the
samples. We also observed similar staining patterns in our
working cohort, which might be caused by the complexity of
Hippo-YAP1 regulation and the  mechanisms involved in
different  cases.  To  understand  these  mechanisms,  we
analyzed the AR-YAP1 correlation using a publicly available
TCGA dataset. AR is a central player in PCa progression and
is the main regulator of gene transcription in prostate tissue.
Therefore, it is important to determine if YAP1 and AR levels
are  correlated.  At  the  mRNA  level,  AR  and  YAP1  were
positively  correlated.  However,  at  the  protein  level,  this
correlation was negative. This further proved that AR-YAP1
interplay is complex and that not only transcriptional, but
post-transcriptional mechanisms are also involved in their
regulation. Further research is  required to elucidate these
mechanisms.
YAP1 is a transcription cofactor and is believed to act as an
oncogene in the nucleus by promoting cell proliferation and
inhibiting apoptosis. Phosphorylation of YAP1, particularly
at serine 127, generates a 14-3-3 binding site that leads to
YAP1 moving from the nucleus to the cytoplasm32-34. YAP1
becomes inactivated by this relocalization and its ability to
act as a co-activator is diminished32,35. We could not relate
the dysregulation of YAP1 expression to its phosphorylation
status  and  the  cytoplasmic  versus  nuclear  localization  of
pYAP1 because the staining intensity of pYAP1 was 1 in the
cytoplasm and 0 in nucleus of all normal, PIN, and cancerous
tissues. Consistent with the tissue samples, both normal cells
(RWPE1) and cancer cells  expressed pYAP1 and YAP1 in
varying degrees.
The results suggested that YAP1 is an indicator of EPE,
which led us to question whether YAP1 might have a role in
metastasis.  When we analyzed PCa tissue and its matched
metastatic tissue, there was no difference in the YAP1 mRNA
leve l .  However ,  we  need  to  keep  in  mind  that
posttranscriptional  mechanisms  may  be  involved  in  the
analyzed sample set.  Kang et al.10  observed that in gastric
cancer  and normal  gastric  mucosa,  the YAP1 mRNA and
protein level  did  not  correlate.  Although the  mean YAP1
mRNA expression was not higher in tumor tissue than in
paired adjacent normal tissue, YAP1 was abundant in cancer
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Figure 4   Expression of YAP1 and AR in protein and mRNA level
and their correlation in PCa cell lines. (A) Western blot analysis of
YAP1  and  AR  revealed  that  the  YAP1  protein  was  high  in  AR
negative (DU145, PC3 and RWPE1) prostate cell lines. (B) Real time
PCR analysis of AR mRNA level in prostate cell lines (The order of
cell lines represented in the graph is the same as in figure C). (C)
Real time PCR analysis of YAP1 mRNA level in prostate cell lines.
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tissue,  whereas it  was rare in normal adjacent tissue.  In a
recent  study  by  Lee  et  al.,36  where  the  transition  in  PCa
progression from a local tumor to lymph node metastasis was
modeled by transplanting mice with PC3 cells orthotopically,
YAP1 expression was  reported to  be  different  in  primary
tumors and lymph nodes. In the primary tumor, fewer cells
expressed YAP1 compared with the number of YAP1-positive
cells in the lymph nodes. As a result, the staining intensity of
YAP1 was higher in the metastatic samples. They suggested
that biophysical cues present in the lymphatics and/or lymph
nodes contributed to high YAP1 expression in metastases. It
would be of particular relevance to examine YAP1 expression
at  the  protein  level  in  matched  local  and  metastatic  PCa
tissue specimens to better understand its  function in PCa
metastasis.
Although the YAP1 staining intensity was generally higher
in normal adjacent tissue compared to that in the cancerous
areas in our patient cohort of primary PCa, YAP1 was still
present and was moderately expressed in the cancer tissues.
Further in vitro functional analyses in PCa cell models as well
as animal studies should be performed to better understand
the role of YAP1 in PCa tumorigenesis.
Acknowledgements
This  work is  financially  supported by  the  The Scientific  and
Technological Research Council of Turkey (TUBITAK, Grant
No.  114S419)  and  Istanbul  Medeniyet  University  Scientific
Research Grants (Grant No. FBA-2014-293).
Conflict of interest statement
No potential conflicts of interest are disclosed.
References
Camargo FD, Gokhale S, Johnnidis JB, Fu DD, Bell GW, Jaenisch R,
et al. YAP1 ıncreases organ size and expands undifferentiated
progenitor cells. Curr Biol. 2007; 17: 2054-60.
1.
Guo LW, Teng LS. YAP/TAZ for cancer therapy: opportunities and
challenges (review). Int J Oncol. 2015; 46: 1444-52.
2.
Ota M, Sasaki H. Mammalian Tead proteins regulate cell
proliferation and contact inhibition as transcriptional mediators of
Hippo signaling. Development. 2008; 135: 4059-69.
3.
Kodaka M, Hata Y. The mammalian Hippo pathway: Regulation
and function of YAP1 and TAZ. Cell Mol Life Sci. 2015; 72:
285-306.
4.
Matallanas D, Romano D, Hamilton G, Kolch W, O’Neill E. A
Hippo in the ointment: MST signalling beyond the fly. Cell Cycle.
2008; 7: 879-84.
5.
Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and
TAZ in cancer. Nat Rev Cancer. 2015; 15: 73-9.
6.
Kim SK, Jung WH, Koo JS. Yes-associated protein (YAP) is
differentially expressed in tumor and stroma according to the
molecular subtype of breast cancer. Int J Clin Exp Pathol. 2014; 7:
3224-34.
7.
Kim GJ, Kim H, Park YN. Increased expression of yes-associated
protein 1 in hepatocellular carcinoma with stemness and combined
hepatocellular-cholangiocarcinoma. PLoS One. 2013; 8: e75449.
8.
Wang LJ, Shi SJ, Guo ZY, Zhang X, Han SX, Yang AG, et al.
Overexpression of YAP and TAZ Is an ındependent predictor of
prognosis in colorectal cancer and related to the proliferation and
metastasis of colon cancer cells. PLoS One. 2013; 8: e65539.
9.
Kang W, Tong JHM, Chan AWH, Lee TL, Lung RWM, Leung PPS,
et al. Yes-associated protein 1 exhibits oncogenic property in gastric
cancer and its nuclear accumulation associates with poor prognosis.
Clin Cancer Res. 2011; 17: 2130-9.
10.
Diep CH, Zucker KM, Hostetter G, Watanabe A, Hu C, Munoz
RM, Von Hoff DD, et al. Down-regulation of yes associated protein
1 expression reduces cell proliferation and clonogenicity of
pancreatic cancer cells. PLoS One. 2012; 7: e32783.
11.
Muramatsu T, Imoto I, Matsui T, Kozaki KI, Haruki S, Sudol M, et
al. YAP is a candidate oncogene for esophageal squamous cell
carcinoma. Carcinogenesis. 2011; 32: 389-98.
12.
Yuan M, Tomlinson V, Lara R, Holliday D, Chelala C, Harada T,
et al. Yes-associated protein (YAP) functions as a tumor suppressor
in breast. Cell Death Differ. 2008; 15: 1752-9.
13.
Hu XY, Jia YY, Yu JJ, Chen J, Fu Q. Loss of YAP protein in PCa is
associated with Gleason score increase. Tumori. 2015; 101: 189-93.
14.
Sheng X, Li WB, Wang DL, Chen KH, Cao JJ, Luo Z, et al. YAP is
closely correlated with castration-resistant PCa, and
downregulation of YAP reduces proliferation and induces apoptosis
of PC-3 cells. Mol Med Rep. 2015; 12: 4867-76.
15.
Zhang L, Yang SP, Chen XC, Stauffer S, Yu F, Lele SM, et al. The
hippo pathway effector YAP regulates motility, invasion, and
castration-resistant growth of PCa cells. Mol Cell Biol. 2015; 35:
1350-62.
16.
Cerami E, Gao JJ, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA,
et al. The cBio cancer genomics portal: an open platform for
exploring multidimensional cancer genomics data. Cancer Discov.
2012; 2: 401-4.
17.
Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO,
et al. Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 2013; 6: pl1.
18.
Liu TB, Liu YD, Gao HY, Meng FL, Yang SS, Lou G. Clinical
significance of yes-associated protein overexpression in cervical
carcinoma. Int J Gynecol Cancer. 2013; 23: 735-42.
19.
Zhao B, Wei XM, Li WQ, Udan RS, Yang Q, Kim J, et al.
Inactivation of YAP oncoprotein by the Hippo pathway is involved
in cell contact inhibition and tissue growth control. Genes Dev.
2007; 21: 2747-61.
20.
Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al.
Transforming properties of YAP, a candidate oncogene on the
21.
412 Collak et al. YAP1 and pYAP1 protein in human PCa
chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 2006; 103:
12405-10.
Weber RG, Sommer C, Albert FK, Kiessling M, Cremer T.
Clinically distinct subgroups of glioblastoma multiforme studied by
comparative genomic hybridization. Lab Invest. 1996; 74: 108-19.
22.
Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan
RCK, et al. Rare amplicons implicate frequent deregulation of cell
fate specification pathways in oral squamous cell carcinoma.
Oncogene. 2005; 24: 4232-42.
23.
Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T,
Karikari CA, et al. Array-based comparative genomic hybridization
identifies localized DNA amplifications and homozygous deletions
in pancreatic cancer. Neoplasia. 2005; 7: 556-62.
24.
Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, Raval A,
et al. A comprehensive search for DNA amplification in lung cancer
identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate
oncogenes. Hum Mol Genet. 2003; 12: 791-801.
25.
Lambros MBK, Fiegler H, Jones A, Gorman P, Roylance RR, Carter
NP, et al. Analysis of ovarian cancer cell lines using array-based
comparative genomic hybridization. J Pathol. 2005; 205: 29-40.
26.
Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi
S, et al. Expression of cIAP1, a target for 11q22 amplification,
correlates with resistance of cervical cancers to radiotherapy.
Cancer Res. 2002; 62: 4860-6.
27.
Dahiya R, McCarville J, Lee C, Hu WX, Kaur G, Carroll P, et al.
Deletion of chromosome 11p15, p12, q22, q23-24 loci in human
PCa. Int J Cancer. 1997; 72: 283-8.
28.
Jiang N, Hjorth-Jensen K, Hekmat O, Iglesias-Gato D, Kruse T,
Wang C, et al. In vivo quantitative phosphoproteomic profiling
identifies novel regulators of castration-resistant PCa growth.
29.
Oncogene. 2015; 34: 2764-76.
Kim TD, Jin F, Shin S, Oh S, Lightfoot SA, Grande JP, et al. Histone
demethylase JMJD2A drives prostate tumorigenesis through
transcription factor ETV1. J Clin Invest. 2016; 126: 706-20.
30.
Kuser-Abali G, Alptekin A, Lewis M, Garraway IP, Cinar B. YAP1
and AR interactions contribute to the switch from androgen-
dependent to castration-resistant growth in PCa. Nat Commun.
2015; 6: 8126.
31.
Zhao B, Li L, Lei QY, Guan KL. The Hippo-YAP pathway in organ
size control and tumorigenesis: an updated version. Genes Dev.
2010; 24: 862-74.
32.
Oh H, Irvine KD. In vivo regulation of Yorkie phosphorylation and
localization. Development. 2008; 135: 1081-8.
33.
Lei QY, Zhang H, Zhao B, Zha ZY, Bai F, Pei XH, et al. TAZ
promotes cell proliferation and epithelial-mesenchymal transition
and ıs ınhibited by the hippo pathway. Mol Cell Biol. 2008; 28:
2426-36.
34.
Nishioka N, Inoue KI, Adachi K, et al. The hippo signaling pathway
components lats and YAP pattern Tead4 activity to distinguish
mouse trophectoderm from ınner cell mass. Dev Cell. 2009; 16:
398-410.
35.
Lee HJ, Diaz MF, Price KM, Ozuna JA, Zhang S, Sevick-Muraca
EM, et al. Fluid shear stress activates YAP1 to promote cancer cell
motility. Nat Commun. 2017; 8: 14122.
36.
Cite  this  article  as:  Collak  FK,  Demir  U,  Ozkanli  S,  Kurum E,  Zerk  PE.
Increased expression of YAP1 in prostate cancer correlates with extraprostatic
extension.  Cancer Biol  Med. 2017;  14:  405-13.  doi:  10.20892/j.issn.2095-
3941.2017.0083
Cancer Biol Med Vol 14, No 4 November 2017 413
